Abstract
Brain metastases (BMs) arising from ovarian cancer remain rare. Spinal cord metastases are even rarer, accounting for just 0.4% of total metastatic spinal cord compressions. In this report, we describe a case of a woman in her 70s who developed sequential brain and spinal cord metastases during her treatment for high-grade serous ovarian cancer, without a germline or somaticBRCAmutation. Following completion of neoadjuvant chemotherapy, interval debulking surgery and adjuvant chemotherapy, relapsed disease was ultimately identified as a single BM, curiously mimicking an acoustic neuroma. Subsequently, spinal cord metastases rapidly developed. Throughout, multidisciplinary team meetings guided decisions on patient management. In this report, we highlight the rarity of such a presentation and discuss the possible role of disease pathophysiology, associated systemic anticancer therapy resistance, and treatment possibilities for both cerebral and spinal metastases.
Reference50 articles.
1. ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
2. National Cancer Institute surveillance E and ERP . Ovarian cancer — cancer stat facts. 2022. Available: https://seer.cancer.gov/statfacts/html/ovary.html [Accessed 14 Apr 2023].
3. Cancer Research UK . Ovarian cancer Statistics. 2022. Available: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/ovarian-cancer#heading-One [Accessed 25 Apr 2023].
4. Update on first-line treatment of advanced ovarian carcinoma;Kemp;Int J Womens Health,2013
5. A source of hope for platinum-resistant ovarian cancer?;Blagden;The Lancet,2021